Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain
- PMID: 11753652
- DOI: 10.1038/sj.onc.1204978
Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain
Abstract
The catalytic activity of the c-Abl tyrosine kinase is tightly regulated by its Src homology 3 (SH3) domain through a complex mechanism that may involve intramolecular binding to Pro242 in the linker region between the SH2 and catalytic domains as well as interactions with a trans-inhibitor. We analysed the effect of mutation or replacement of SH3 on c-Abl tyrosine kinase activity and transformation. Random mutagenesis of SH3 identified several novel point mutations that dysregulated c-Abl kinase activity in vivo, but the RT loop was insensitive to mutational activation. Activating SH3 mutations abolished binding of proline-rich SH3 ligands in vitro, while mutations at Ser140 in the connector between the SH3 and SH2 domains activated Abl kinase activity in vivo and in vitro but did not impair SH3 ligand-binding. Abl was regulated efficiently when its SH3 domain was replaced with a heterologous SH3 from c-Src that binds a different spectrum of proline-rich ligands, but not by substitution of a modular WW domain with similar ligand-binding specificity. These results suggest that the SH3 domain regulates Abl principally by binding to the atypical intramolecular ligand Pro242 rather than a canonical PxxP ligand. Coordination between the SH3 and SH2 domains mediated by the connector region may be required for regulation of Abl even in the absence of SH2 ligand binding.
Similar articles
-
Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro.Oncogene. 1995 May 18;10(10):1977-88. Oncogene. 1995. PMID: 7539119
-
An intramolecular SH3-domain interaction regulates c-Abl activity.Nat Genet. 1998 Mar;18(3):280-2. doi: 10.1038/ng0398-280. Nat Genet. 1998. PMID: 9500553
-
Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.J Mol Biol. 1998 Aug 21;281(3):513-21. doi: 10.1006/jmbi.1998.1932. J Mol Biol. 1998. PMID: 9698566
-
Regulation of the c-Abl and Bcr-Abl tyrosine kinases.Nat Rev Mol Cell Biol. 2004 Jan;5(1):33-44. doi: 10.1038/nrm1280. Nat Rev Mol Cell Biol. 2004. PMID: 14708008 Review.
-
SH3 domain ligand binding: What's the consensus and where's the specificity?FEBS Lett. 2012 Aug 14;586(17):2609-14. doi: 10.1016/j.febslet.2012.04.042. Epub 2012 May 2. FEBS Lett. 2012. PMID: 22710157 Review.
Cited by
-
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9244-9. doi: 10.1073/pnas.0600001103. Epub 2006 Jun 5. Proc Natl Acad Sci U S A. 2006. PMID: 16754879 Free PMC article.
-
Autoinhibition of Bcr-Abl through its SH3 domain.Mol Cell. 2003 Jul;12(1):27-37. doi: 10.1016/s1097-2765(03)00274-0. Mol Cell. 2003. PMID: 12887890 Free PMC article.
-
Mutation of Vav1 adaptor region reveals a new oncogenic activation.Oncotarget. 2015 Feb 10;6(4):2524-37. doi: 10.18632/oncotarget.2629. Oncotarget. 2015. PMID: 25426554 Free PMC article.
-
Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signaling complex.Cell Mol Life Sci. 2020 Oct;77(19):3885-3903. doi: 10.1007/s00018-019-03397-7. Epub 2019 Dec 9. Cell Mol Life Sci. 2020. PMID: 31820037 Free PMC article.
-
Cdo binds Abl to promote p38alpha/beta mitogen-activated protein kinase activity and myogenic differentiation.Mol Cell Biol. 2009 Aug;29(15):4130-43. doi: 10.1128/MCB.00199-09. Epub 2009 May 26. Mol Cell Biol. 2009. PMID: 19470755 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous